Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension

Clin Exp Hypertens. 1998 Oct;20(7):751-61. doi: 10.3109/10641969809052117.

Abstract

Objectives: To assess the effects of a vasodilatory beta-adrenoceptor blocker, nipradilol, and a long-acting Ca channel blocker, barnidipine, on insulin sensitivity.

Design: Insulin sensitivity was determined using a euglycemic hyperinsulinemic clamp technique before and after a 12-week treatment period in eighteen patients with essential hypertension.

Results: Both drugs decreased blood pressure without affecting any serum parameters of glucose and lipid metabolism. Nipradilol significantly augmented glucose infusion rate (GIR) from 3.11+/-0.28 to 4.69+/-0.57mg/kg/min (p=0.027). Barnidipine also increased GIR from 3.91+/-0.43 to 5.29+/-0.43 mg/kg/min (p=0.028). Plasma norepinephrine concentrations significantly increased with barnidipine treatment, while nipradilol had no effect on plasma norepinephrine levels. No adverse events were reported during the study.

Conclusions: These results suggest that vasodilatory beta-blockers such as nipradilol and long-acting Ca channel blockers such as barnidipine may be useful in the treatment of insulin resistant hypertensive patients.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / therapeutic use*
  • Female
  • Glucose Clamp Technique
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / physiopathology*
  • Insulin Resistance / physiology*
  • Male
  • Middle Aged
  • Nifedipine / analogs & derivatives*
  • Nifedipine / therapeutic use
  • Propanolamines / therapeutic use*
  • Vasodilator Agents / therapeutic use*

Substances

  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Propanolamines
  • Vasodilator Agents
  • mepirodipine
  • nipradilol
  • Nifedipine